<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">WJCR</journal-id><journal-title-group><journal-title>World Journal of Cancer Research</journal-title></journal-title-group><issn pub-type="epub">2164-9049</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/WJCR.2019.93012</article-id><article-id pub-id-type="publisher-id">WJCR-31430</article-id><article-categories><subj-group subj-group-type="heading"><subject>WJCR20190300000_67507980.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  TMEM176B调控乳腺癌凋亡作用及机制研究
  The Mechanism of TMEM176B in Apoptosis of Breast Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>翀</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>苏</surname><given-names>宝倡</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>暨南大学附属华侨医院，广东 广州</addr-line></aff><aff id="aff2"><addr-line>广州卫生职业技术学院，广东 广州</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>25</day><month>07</month><year>2019</year></pub-date><volume>09</volume><issue>03</issue><fpage>82</fpage><lpage>89</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：研究跨膜蛋白176B (Transmembrane protein 176B, TMEM176B)在乳腺癌中凋亡作用及机制。方法：qRT-PCR、western blot法检测乳腺癌组织中TMEM176B表达；小分子干扰RNA和干扰TMEM176B后研究其作用和分子机制。MTT法和CCK8实验检测乳腺癌细胞生长情况；流式细胞实验检测乳腺癌凋亡作用。结果：干扰TMEM176B后明显抑制乳腺癌活力和诱导乳腺癌凋亡，抑制细胞增殖蛋白Ki67表达，且下调抑凋亡蛋白Bcl-2和上调促凋亡蛋白Bax表达水平。在机制方面，我们发现干扰TMEM176B后下调p53表达和p-AKT水平。结论：TMEM176B通过调控p53表达和p-AKT水平进而调控乳腺癌凋亡作用。
    Objective: To study the role and mechanism of transmembrane protein 176B (TMEM176B) in breast cancer. Methods: The expression of TMEM176B in breast cancer tissue was detected by qRT-PCR and Western blot, and using small interfering RNA for silencing TMEM176B level. MTT assay and CCK8 assay were used to detect the viability of breast cancer cells, and flow cytometry was used to detect the apoptosis of breast cancer cells. Results: Small interfering RNA significantly knocked down the level of TMEM176B, inhibited the growth of breast cancer. In terms of mechanism, siRNA inhibited the cell proliferation protein Ki67 expression, and down-regulated the expression of apoptotic protein Bcl-2 and up-regulated the expression of apoptotic protein Bax. Furthermore, the result showed that the expression of p53 and the level of p-AKT were down-regulated after TMEM176B interference. Conclusion: knockdown of TMEM176B promotes the apoptosis of breast cancer by regulating the expression of p53 and the level of p-AKT. 
  
 
</p></abstract><kwd-group><kwd>乳腺癌，TMEM176B，Bcl-2，Bax，Ki67，p53和p-AKT信号通路, Breast Cancer</kwd><kwd> TMEM176B</kwd><kwd> Bcl-2</kwd><kwd> Bax</kwd><kwd> Ki67</kwd><kwd> P53 and P-AKT Signaling Pathways</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>TMEM176B调控乳腺癌凋亡作用及机制研究<sup> </sup></title><p>杨翀<sup>1</sup>，苏宝倡<sup>2*</sup></p><p><sup>1</sup>广州卫生职业技术学院，广东 广州</p><p><sup>2</sup>暨南大学附属华侨医院，广东 广州</p><p><img src="//html.hanspub.org/file/2-2150178x1_hanspub.png" /></p><p>收稿日期：2019年6月26日；录用日期：2019年7月18日；发布日期：2019年7月25日</p><disp-formula id="hanspub.31430-formula31"><graphic xlink:href="//html.hanspub.org/file/2-2150178x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：研究跨膜蛋白176B (Transmembrane protein 176B, TMEM176B)在乳腺癌中凋亡作用及机制。方法：qRT-PCR、western blot法检测乳腺癌组织中TMEM176B表达；小分子干扰RNA和干扰TMEM176B后研究其作用和分子机制。MTT法和CCK8实验检测乳腺癌细胞生长情况；流式细胞实验检测乳腺癌凋亡作用。结果：干扰TMEM176B后明显抑制乳腺癌活力和诱导乳腺癌凋亡，抑制细胞增殖蛋白Ki67表达，且下调抑凋亡蛋白Bcl-2和上调促凋亡蛋白Bax表达水平。在机制方面，我们发现干扰TMEM176B后下调p53表达和p-AKT水平。结论：TMEM176B通过调控p53表达和p-AKT水平进而调控乳腺癌凋亡作用。</p><p>关键词 :乳腺癌，TMEM176B，Bcl-2，Bax，Ki67，p53和p-AKT信号通路</p><disp-formula id="hanspub.31430-formula32"><graphic xlink:href="//html.hanspub.org/file/2-2150178x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/2-2150178x8_hanspub.png" /> <img src="//html.hanspub.org/file/2-2150178x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>乳腺癌是最常见的恶性肿瘤之一，近年来已成为全球女性第二大死因 [<xref ref-type="bibr" rid="hanspub.31430-ref1">1</xref>]。2015年，约430万中国妇女诊断患有乳腺癌，其中75%人死于乳腺癌 [<xref ref-type="bibr" rid="hanspub.31430-ref2">2</xref>]。乳腺癌治疗包括外科手术切除、化疗、放疗、内分泌治疗、靶向治疗和其他补充治疗 [<xref ref-type="bibr" rid="hanspub.31430-ref3">3</xref>]。但是，这些传统治疗方法大多数会产生副作用或疗效不佳。因此，寻找新的靶点抑制乳腺癌生长和诱导其凋亡，可延长乳腺癌患者生存期和改善生活质量。跨膜蛋白176B (Transmembrane protein 176B, TMEM176B)，也称为耐受相关诱导蛋白，是一种免疫调节的阳离子通道 [<xref ref-type="bibr" rid="hanspub.31430-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.31430-ref5">5</xref>]。TMEM176B蛋白包含四个跨膜结构域及C端的ITIM基序。TMEM176B及其同源TMEM176A是MS4A蛋白家族的成员 [<xref ref-type="bibr" rid="hanspub.31430-ref6">6</xref>]，主要表达于单核细胞、巨噬细胞和CD11B<sup>+</sup>树突状细胞 [<xref ref-type="bibr" rid="hanspub.31430-ref7">7</xref>]。随后研究发现TMEM176B广泛存在于肺脏、肝脏、肾等 [<xref ref-type="bibr" rid="hanspub.31430-ref8">8</xref>]。最近研究发现TMEM176B调控肿瘤微环境中免疫细胞功能，且阻断TMEM176B后增强抗肿瘤免疫作用 [<xref ref-type="bibr" rid="hanspub.31430-ref9">9</xref>]。但是，TMEM176B在乳腺癌中表达及其对乳腺癌作用和分子机制尚未清楚。</p><p>在这篇文章中，我们探讨TMEM176B在乳腺癌中表达及其在乳腺癌中作用，同时阐明其分子机制。本文采用小分子干扰片段敲低乳腺癌细胞TMEM176B表达，用MTT实验、CCK8实验和流式细胞实验检测乳腺癌生长和凋亡情况。同时检测相关凋亡蛋白Bax\Bcl-2、增殖蛋白Ki67，以及抑癌基因p53和AKT信号通路，初步阐明TMEM176B在乳腺癌癌中作用及分子机制。此外，我们也初步评估TMEM176B在乳腺癌诊断中价值。</p></sec><sec id="s4"><title>2. 材料与方法</title><sec id="s4_1"><title>2.1. 细胞培养</title><p>乳腺癌细胞株MDA-MB-231购自ATCC。用DMEM+10%的胎牛血清完全培养基无菌于37˚、5% CO<sub>2</sub>的细胞培养箱中培养。</p></sec><sec id="s4_2"><title>2.2. 试剂和耗材</title><p>MTT购自北京鼎国公司。CCK8试剂盒购自乐研生物公司。Real time PCR的SYBER Green和逆转录酶试剂盒购自Takara公司。RNA提取试剂盒购自TIANGEN公司。干扰TMEM176B的siRNA小分子干扰片段购自上海吉玛公司。转染试剂Lipo3000购自Invtrogen公司。细胞培养液购Hyclone公司。TMEM176B抗体购自Proteintech公司；Bax、Bcl-2、p53、Ki67、β-actin抗体购自Abcam公司。</p></sec><sec id="s4_3"><title>2.3. 方法</title><p>MTT法检测乳腺癌细胞活力：采用噻唑兰颜色反应法，即MTT法进行细胞增殖活力的测定。其原理为活细胞线粒体中的琥珀酸脱氢酶能使外源性MTT还原为水不溶性的蓝紫色晶体甲缵，并沉淀在细胞中，而死细胞无此功能。MDA-MB-231细胞种植于96孔板，转染siRNA-TMEM176B，处理24 h后，每孔加入10 &#181;l的MTT工作液(浓度为5 mg/ml)，于37˚、5% CO<sub>2</sub>的细胞培养箱中继续培养4小时；去掉上清，加入150 &#181;l DMSO，1000转/min，摇床震荡10 min，用酶标仪测定OD<sub>490</sub>的光密度值。实验中每份样品设6个复孔，实验至少重复3次。</p><p>CCK8法检测乳腺癌细胞活力：该试剂中含有WST-8，它在电子载体1-Methoxy PMS的作用下被细胞中的脱氢酶还原为具有高度水溶性的黄色甲瓒产物。生成的甲瓒物的数量与活细胞的数量成正比。每孔接种5000个细胞，设定6个重复孔，细胞贴壁后，转染siRNA-TMEM176B，24 h后加入PBS润洗后吸出，加入稀释好的CCK8溶液，放入培养箱中30 min后测定OD值。</p><p>qRT-PCR实验</p><p>qRT-PCR检测乳腺癌组织TMEM176B的转录水平。步骤如下：收集20例乳腺癌组织，以癌旁组织为对照组，提取RNA，逆转录为cDNA，用Takara公司的SYBER green试剂盒进行实时荧光PCR实验。PCR条件为：95℃ 30 s，1个循环；PCR反应，95℃ 5 s，60℃ 10 s，40个循环；溶解，95℃ 0 s，65℃ 20 s，95℃ 0 s，1个循环。PCR结束后，根据反应得到的Cp值，使用相对定量的分析方法，以标准曲线进行校正，最后计算出样品中各mRNA的相对浓度。进行qRT-PCR引物序列如表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The primer of qRT-PC</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >NCBI ID</th><th align="center" valign="middle" >基因</th><th align="center" valign="middle" >引物</th><th align="center" valign="middle" >引物序列</th><th align="center" valign="middle" >退火温度</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >NM_NM_001101311.1</td><td align="center" valign="middle"  rowspan="2"  >TMEM176B</td><td align="center" valign="middle" >上游</td><td align="center" valign="middle" >5’-TACATGCAGATGCTGAGGAAG-3’</td><td align="center" valign="middle"  rowspan="2"  >60℃</td></tr><tr><td align="center" valign="middle" >下游</td><td align="center" valign="middle" >5’-GAAGACCTACTCCCAAGGAAAC-3’</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >NM_002046.5</td><td align="center" valign="middle"  rowspan="2"  >GAPDH</td><td align="center" valign="middle" >上游</td><td align="center" valign="middle" >5’-ACCATCTTCCAGGAGCGAGA-3’</td><td align="center" valign="middle"  rowspan="2"  >60℃</td></tr><tr><td align="center" valign="middle" >下游</td><td align="center" valign="middle" >5’-GACTCCACGACGTACTCAGC-3’</td></tr></tbody></table></table-wrap><p>表1. 实时荧光定量PCR引物</p><p>干扰TMEM176B实验</p><p>TMEM176B干扰小分子片段siRAN购自上海吉玛公司。</p><p>具体步骤如下：MDA-MB-231细胞种植于六孔板中，待其融合度为50%~60%时候，用Lipo3000转染试剂转染干扰小分子片段siRNA，一定时间后进行MTT实验、CCK8实验和流式细胞实验。</p><p>流式细胞实验</p><p>MDA-MB-231细胞种植于六孔板中，待其融合度为50%~60%时候，用Lipo3000转染试剂转染干扰小分子片段siRNA，24小时后收集细胞，重悬在1 &#215; binding buffer中，调浓度为1 &#215; 10<sup>6</sup>/ml，加入PI和Annexin V，孵育15 min，流式细胞仪分析。</p><p>Western blot实验</p><p>收集处理好的乳腺癌细胞蛋白或乳腺癌组织蛋白，进行蛋白定量，跑胶，电转电泳。加入一抗，4度过夜，收集一抗，加入二抗，然后加入ECL显色，拍照。</p></sec><sec id="s4_4"><title>2.4. 统计学分析</title><p>采用SPSS17.0软件进行统计学处理。计量资料以均数&#177;标准差表示。采用t检验。P &lt; 0.05表示具有统计学意义。</p></sec></sec><sec id="s5"><title>3. 实验结果</title><sec id="s5_1"><title>3.1. 乳腺癌组织中TMEM176B表达情况</title><p>收集诊断为乳腺癌患者的乳腺癌组织，取癌旁组织为对照组。采用实时荧光PCR和Western blot分别检测TMEM176B在乳腺组织中表达。结果显示，相对于癌旁组织，TMEM176B在乳腺癌组织中高表达(图1(A)和图1(B))。</p><p>图1. TMEM176B在乳腺癌组织中表达</p></sec><sec id="s5_2"><title>3.2. TMEM176B在乳腺癌细胞中作用</title><p>用小分子干扰片段siRNA转染MDA-MB-231细胞，进行MTT实验、CCK8实验检测乳腺癌细胞活力，以及流式细胞实验检测乳腺癌细胞凋亡作用。结果显示，小分子干扰片段siRNA敲低乳腺癌细胞TMEM176B后，乳腺癌细胞活力明显受抑制(图2(A)和图2(B))。流式细胞实验结果显示干扰TMEM176B后诱导乳腺癌细胞凋亡(图2(C))。这些结果表明TMEM176B调控乳腺癌细胞的凋亡过程。</p></sec><sec id="s5_3"><title>3.3. TMEM176B调控乳腺癌细胞相关凋亡蛋白Bax/Bcl-2和增殖蛋白Ki67表达</title><p>为了阐明TMEM176B调控乳腺癌细胞生长和凋亡作用的分子机制，我们检测凋亡相关蛋白Bax和Bcl-2表达。结果显示，干扰TMEM176B后明显上调促凋亡蛋白Bax表达，抑制抑凋亡蛋白Bcl-2表达(图3(A))，明显上调Bax/Bcl-2比例(图3(B))。此外，我们也检测了增殖蛋白Ki67情况。图3(C)显示，沉默TMEM176B后明显下调Ki67蛋白表达。这些结果表明敲低TMEM176B后可能通过调控凋亡蛋白Bax/Bcl-2和增殖蛋白Ki67表达进而调控乳腺癌细胞凋亡作用。</p><p>(图3(A)和图3(B)) TMEM176B调控乳腺癌细胞Bax和Bcl-2蛋白表达。小分子RNA敲低TMEM176B后，于24 h收集细胞蛋白检测Bax和Bcl-2表达。<sup>**</sup>p &lt; 0.01。图3(C) TMEM176B调控乳腺癌细胞Ki67蛋白表达。小分子RNA敲低TMEM176B后，于24 h收集细胞蛋白检测Ki67表达。</p><p>图2. 敲低TMEM176B后抑制乳腺癌细胞生长和诱导其凋亡</p><p>图3. TMEM176B调控乳腺癌细胞Bax/Bcl-2和Ki67蛋白表达</p></sec><sec id="s5_4"><title>3.4. TMEM176B调控乳腺癌细胞p53和p-AKT水平</title><p>为了进一步阐明TMEM176B调控乳腺癌细胞凋亡作用的分子机制，我们检测抑癌p53蛋白和p-AKT水平。结果显示，干扰TMEM176B后，上调抑癌p53蛋白表达和下调p-AKT水平(图4(A)和图4(B))。以上结果表明，TMEM176B可能通过p53和p-AKT通路调控凋亡相关蛋白Bax/Bcl-2和增殖蛋白Ki67表达，进而调控乳腺癌凋亡作用。</p></sec><sec id="s5_5"><title>3.5. TMEM176B在乳腺癌诊断价值评估</title><p>为了评估TMEM176B在乳腺癌诊断中价值，我们进行了ROC曲线分析。结果显示，TMEM176B在乳腺癌诊断中具有较好价值，AUC面积为0.919 (图5(A))。同时ROC曲线分析表明TMEM176B对乳腺癌诊断敏感性和特异性分别为81.5%和89.5%；95%置信区间为0.832~1.005 (图5(B))。</p><p>图4. 干扰TMEM176B后上调乳腺癌细胞p53蛋白表达和下调p-AKT水平</p><p>图5. TMEM176B在乳腺癌诊断中评估</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>乳腺癌在女性恶性肿瘤中排第一位，虽然近几年治疗水平提高，患者病情得到很好的控制。但是，发生远处转移的患者平均生存率极低(低于24个月) [<xref ref-type="bibr" rid="hanspub.31430-ref10">10</xref>]。因此，寻找新的靶点诱导乳腺癌凋亡有望提高乳腺癌患者的生存期。人TMEM176B最初发现于人肺成纤维细胞中 [<xref ref-type="bibr" rid="hanspub.31430-ref11">11</xref>]，最近研究发现其与小细胞肺癌有关 [<xref ref-type="bibr" rid="hanspub.31430-ref12">12</xref>]。越来越多证据表明TMEM176B与肿瘤发生发展密切相关。TMEM176B蛋白异常积累与癌症的发病机制显著相关 [<xref ref-type="bibr" rid="hanspub.31430-ref13">13</xref>]，并且在胃肠道肿瘤中TMEM176B高表达 [<xref ref-type="bibr" rid="hanspub.31430-ref14">14</xref>]。但是，TMEM176B在乳腺癌凋亡中作用及分子机制尚未清楚。我们研究发现TMEM176B在乳腺癌中高表达，且敲低TMEM176B后抑制乳腺癌细胞生长和诱导其凋亡。分子机制方面，我们发现TMEM176B调控凋亡相关蛋白Bax/Bcl-2、增殖蛋白Ki67、抑癌基因p53表达和p-AKT水平。此外，ROC曲线分析表明TMEM176B对乳腺癌诊断有良好价值，可辅助乳腺癌诊断。</p><p>细胞凋亡也是肿瘤的一个重要特征 [<xref ref-type="bibr" rid="hanspub.31430-ref15">15</xref>]。细胞凋亡主要由细胞凋亡蛋白Bcl-2家族调控。Bcl-2家族包括促凋亡蛋白Bak和Bax以及抑凋亡蛋白Bcl-2和Mcl-1 [<xref ref-type="bibr" rid="hanspub.31430-ref16">16</xref>]。我们实验中发现敲低TMEM176B后明显上调促凋亡蛋白Bax水平，下调抑凋亡蛋白Bcl-2水平，明显升高Bax/Bcl-2比例；且功能实验表明阻断TMEM176B后抑制乳腺癌生长和诱导凋亡，表明TMEM176B可能通过调控凋亡蛋白Bcl-2家族调控进而调控乳腺癌凋亡过程。抑癌基因p53作为细胞应激传感器而发挥作用，由DNA损伤和癌基因激活等应激条件激活，在肿瘤凋亡中起着重要作用。正常情况下，p53蛋白水平较低，这是由于p53靶向E3泛素蛋白连接酶mdm2的反馈调节，后者靶向p53进行蛋白酶体介导的降解 [<xref ref-type="bibr" rid="hanspub.31430-ref16">16</xref>]。我们实验发现TMEM176B也可调控p53蛋白表达。PI3K-Akt信号通路在乳腺癌的发展中起着重要作用。p-Akt作为这一途径中最关键的信号分子，作为一种治疗靶点引起了广泛的关注 [<xref ref-type="bibr" rid="hanspub.31430-ref17">17</xref>]。在我们实验中，发现沉默TMEM176B后下调p-Akt，提示TMEM176B也可能作为p-Akt抑制剂成为治疗乳腺癌新的靶点。此外，ROC曲线表明TMEM176B也是乳腺癌诊断的潜在指标。但是，TMEM176B在体内是否调控乳腺癌凋亡过程以及TMEM176B如何调控p53蛋白表达和p-Akt水平尚需进一步研究，这也是本文不足之处。</p><p>总之，在这篇论文中我们研究TMEM176B在乳腺癌中作用和初步探讨分子机制，同时分析其在乳腺癌中诊断价值。我们发现阻断TMEM176B后抑制乳腺癌细胞生长和诱导其凋亡，其机制与Bax/Bcl-2、Ki67、抑癌基因p53和p-AKT通路有关，这些结果表明靶向TMEM176B可诱导乳腺癌凋亡，为将来临床靶向TMEM176B治疗乳腺癌提供实验基础，具有一定的临床意义。</p></sec><sec id="s7"><title>文章引用</title><p>杨 翀,苏宝倡. TMEM176B调控乳腺癌凋亡作用及机制研究The Mechanism of TMEM176B in Apoptosis of Breast Cancer[J]. 世界肿瘤研究, 2019, 09(03): 82-89. https://doi.org/10.12677/WJCR.2019.93012</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.31430-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Yedjou, C., Izevbigie, E. and Tchounwou, P. (2008) Preclinical Assessment of Vernonia Amygdalina Leaf Extracts as DNA Damaging Anti-Cancer Agent in the Management of Breast Cancer. International Journal of Environmental Re-search and Public Health, 5, 337-341. https://doi.org/10.3390/ijerph5050337</mixed-citation></ref><ref id="hanspub.31430-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Chen, W., et al. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132.  
https://doi.org/10.3322/caac.21338</mixed-citation></ref><ref id="hanspub.31430-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">DeSantis, C.E., et al. (2014) Cancer Treatment and Survivorship Statistics, 2014. CA: A Cancer Journal for Clinicians, 64, 252-271. https://doi.org/10.3322/caac.21235</mixed-citation></ref><ref id="hanspub.31430-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Louvet, C., et al. (2005) Identification of a New Member of the CD20/FcepsilonRIbeta Family Overexpressed in Tolerated Allografts. American Journal of Transplantation, 5, 2143-2153.  
https://doi.org/10.1111/j.1600-6143.2005.01007.x</mixed-citation></ref><ref id="hanspub.31430-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Segovia, M., et al. (2014) Autologous Dendritic Cells Prolong Allograft Survival through Tmem176b-Dependent Antigen Cross-Presentation. American Journal of Trans-plantation, 14, 1021-1031. https://doi.org/10.1111/ajt.12708</mixed-citation></ref><ref id="hanspub.31430-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Eon Kuek, L., et al. (2016) The MS4A Family: Counting Past 1, 2 and 3. Immunology &amp; Cell Biology, 94, 11-23.</mixed-citation></ref><ref id="hanspub.31430-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Condamine, T., et al. (2010) Tmem176B and Tmem176A Are Associated with the Immature State of Dendriticcells. Journal of Leukocyte Biology, 88, 507-515. https://doi.org/10.1189/jlb.1109738</mixed-citation></ref><ref id="hanspub.31430-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Cuajungco, M.P., et al. (2012) Abnormal Accumulation of Human Transmembrane (TMEM)-176A and 176B Proteins Is Associated with Cancer Pathology. Acta Histochemica, 114, 705-712.  
https://doi.org/10.1016/j.acthis.2011.12.006</mixed-citation></ref><ref id="hanspub.31430-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Segovia, M., et al. (2019) Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Acti-vation. Cancer Cell, 35, 767-781.e6.</mixed-citation></ref><ref id="hanspub.31430-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">DeSantis, C., et al. (2014) Breast Cancer Statistics, 2013. CA: A Cancer Journal for Clinicians, 64, 52-62.  
https://doi.org/10.3322/caac.21203</mixed-citation></ref><ref id="hanspub.31430-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Lurton, J., et al. (1999) Isolation of a Gene Product Expressed by a Subpopulation of Human Lung Fibroblasts by Differential Display. American Journal of Respiratory Cell and Molecular Biology, 20, 327-331.  
https://doi.org/10.1165/ajrcmb.20.2.3368</mixed-citation></ref><ref id="hanspub.31430-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Gottschling, S., et al. (2012) Establishment and Comparative Characterization of Novel Squamous Cell Non-Small Cell Lung Cancer Cell Lines and Their Corresponding Tumor Tissue. Lung Cancer, 75, 45-57.  
https://doi.org/10.1016/j.lungcan.2011.05.020</mixed-citation></ref><ref id="hanspub.31430-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Cao, Q., et al. (2016) MicroRNA-7 Inhibits Cell Proliferation, Migration and Invasion in Human Non-Small Cell Lung Cancer Cells by Targeting FAK through ERK/MAPK Signaling Pathway. Oncotarget, 7, 77468-77481.  
https://doi.org/10.18632/oncotarget.12684</mixed-citation></ref><ref id="hanspub.31430-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Lee, C.H., Liang, C.W. and Espinosa, I. (2010) The Utility of Discovered on Gastrointestinal Stromal Tumor 1 (DOG1) Antibody in Surgical Pathology—The GIST of It. Advances in Anatomic Pathology, 17, 222-232.  
https://doi.org/10.1097/PAP.0b013e3181d973c2</mixed-citation></ref><ref id="hanspub.31430-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Su, Z., et al. (2015) Apoptosis, Autophagy, Necroptosis, and Cancer Metastasis. Molecular Cancer, 14, 48.</mixed-citation></ref><ref id="hanspub.31430-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Adams, J.M. and Cory, S. (2007) The Bcl-2 Apoptotic Switch in Cancer Development and Therapy. Oncogene, 26, 1324-1337. https://doi.org/10.1038/sj.onc.1210220</mixed-citation></ref><ref id="hanspub.31430-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Hasson, S.P., et al. (2013) Endocrine Resistance in Breast Cancer: Focus on the Phosphatidylinositol 3-Kinase/Akt/ Mammalian Target of Rapamycin Signaling Pathway. Breast Care (Basel), 8, 248-255.  
https://doi.org/10.1159/000354757</mixed-citation></ref></ref-list></back></article>